IGFBP2 and ovarian carcinoma: Increased IGFBP2 expression has been reported in many malignancies and has been linked to chemoresistance in ovarian cancer [22], breast cancer [23–25], colon cancer [26], lung cancer [27–29], prostate cancer [30, 31], glioma [32–34] and leukemia [35–37].